{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:10:17Z","timestamp":1790111417858,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.08.005","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:57:15Z","timestamp":1789531035000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Performance of the EORTC and CUETO risk prediction models in contemporary patients undergoing transurethral resection of bladder tumor with blue light cystoscopy"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1117-1679","authenticated-orcid":false,"given":"Agustin","family":"Perez-Londo\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumedh","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Fleishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrinath","family":"Konety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Pohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Holzbeierlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Kates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Willard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hristos Z.","family":"Kaimakliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima P.","family":"Porten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Tyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Gershman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.urolonc.2026.08.005_bib0001","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/00005650-199508000-00007","article-title":"Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis","volume":"33","author":"Riley","year":"1995","journal-title":"Medical Care"},{"issue":"5","key":"10.1016\/j.urolonc.2026.08.005_bib0002","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MOU.0000000000000078","article-title":"The burden of bladder cancer care: direct and indirect costs","volume":"24","author":"Mossanen","year":"2014","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2026.08.005_bib0003","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/CEOR.S274951","article-title":"Humanistic and economic burden of non-muscle invasive bladder cancer: results of two systematic literature reviews","volume":"12","author":"Lee","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"issue":"5","key":"10.1016\/j.urolonc.2026.08.005_bib0004","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","article-title":"Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice","volume":"20","author":"Van Hoogstraten","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.08.005_bib0005","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2015.01.032","article-title":"Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature","volume":"68","author":"Kluth","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.005_bib0006","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.08.005_bib0007","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.08.005_bib0008","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.005_bib0009","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology Guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ)\u2014a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.005_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/1756287213510590","article-title":"Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer","volume":"6","author":"Oude Elferink","year":"2014","journal-title":"Therap Adv Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.08.005_bib0011","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.juro.2010.06.148","article-title":"Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer","volume":"184","author":"Stenzl","year":"2010","journal-title":"J Urol"},{"issue":"8b","key":"10.1016\/j.urolonc.2026.08.005_bib0012","doi-asserted-by":"crossref","first-page":"E297","DOI":"10.1111\/j.1464-410X.2011.10090.x","article-title":"Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in T a\/T1 patients: a randomized two-centre study","volume":"108","author":"Hermann","year":"2011","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.005_bib0013","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/01.ju.0000169257.19841.2a","article-title":"Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase iii multicenter study","volume":"174","author":"Jocham","year":"2005","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.08.005_bib0014","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non\u2013muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.005_bib0015","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2026.08.005_bib0016","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.juro.2017.04.077","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in a United States population","volume":"198","author":"Ravvaz","year":"2017","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.08.005_bib0017","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1089\/end.2020.0301","article-title":"The impact of restaging transurethral resection of bladder tumor on survival parameters in T1 nonmuscle-invasive bladder cancer: systematic review and meta-analysis","volume":"34","author":"Krajewski","year":"2020","journal-title":"J Endourol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.08.005_bib0018","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cam4.3007","article-title":"Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): a cohort analysis","volume":"9","author":"Jobczyk","year":"2020","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.005_bib0019","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/JU.0000000000002308","article-title":"Utility of blue light cystoscopy for post-bacillus Calmette-Gu\u00e9rin bladder cancer recurrence detection: implications for clinical trial recruitment and study comparisons","volume":"207","author":"Chappidi","year":"2022","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.005_bib0020","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.eururo.2018.08.038","article-title":"Reporting and interpreting decision curve analysis: a guide for investigators","volume":"74","author":"Van Calster","year":"2018","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.08.005_bib0021","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/CIRCULATIONAHA.106.672402","article-title":"Use and misuse of the receiver operating characteristic curve in risk prediction","volume":"115","author":"Cook","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.005_bib0022","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.08.005_bib0023","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/iju.12572","volume":"21","author":"Kohjimoto","year":"2014","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.005_bib0024","first-page":"169","article-title":"Performance of the EORTC and CUETO models to predict recurrence and progression in high-risk non-muscle-invasive bladder cancer patients","volume":"21","author":"Paz\u0131r","year":"2024","journal-title":"Urol J"},{"issue":"9","key":"10.1016\/j.urolonc.2026.08.005_bib0025","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/cancers16091684","article-title":"Assessing the predictive accuracy of EORTC, CUETO and EAU risk stratification models for high-grade recurrence and progression after Bacillus Calmette\u2013Gu\u00e9rin therapy in non-muscle-invasive bladder cancer","volume":"16","author":"\u015alusarczyk","year":"2024","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.005_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096849","article-title":"Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours","volume":"9","author":"Vedder","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.005_bib0027","doi-asserted-by":"crossref","DOI":"10.1097\/JU9.0000000000000260","article-title":"Oncologic outcomes of blue light cystoscopy in an equal access setting: results of the BRAVO study","volume":"3","author":"Nasrallah","year":"2025","journal-title":"JU Open Plus"},{"key":"10.1016\/j.urolonc.2026.08.005_bib0028","unstructured":"Organisation mondiale de la sant\u00e9, Centre international de recherche sur le cancer, eds. WHO classification of tumours of the urinary system and male genital organs. International agency for research on cancer; 2016."},{"issue":"03","key":"10.1016\/j.urolonc.2026.08.005_bib0029","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7099.1000226","article-title":"Prognostic value of artificial neural network in predicting bladder cancer recurrence after BCG Immunotherapy","volume":"05","author":"Ajili","year":"2014","journal-title":"J Cytol Histol"},{"key":"10.1016\/j.urolonc.2026.08.005_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103601","article-title":"Artificial intelligence: a promising frontier in bladder cancer diagnosis and outcome prediction","volume":"171","author":"Borhani","year":"2022","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.urolonc.2026.08.005_bib0031","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001008848.77629.6f.03","article-title":"Predicting response to intravesical BCG in high-risk NMIBC using an artificial intelligence\u2013powered pathology assay: development and validation in an international 12-center cohort","author":"Lotan","year":"2024","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.005_bib0032","doi-asserted-by":"crossref","first-page":"193.e7","DOI":"10.1016\/j.urolonc.2020.05.009","article-title":"Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer","volume":"39","author":"Bhambhvani","year":"2021","journal-title":"Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:48:25Z","timestamp":1790110105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926006952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"alternative-id":["S1078143926006952"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.005","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Performance of the EORTC and CUETO risk prediction models in contemporary patients undergoing transurethral resection of bladder tumor with blue light cystoscopy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}